1. Zhang C, Liang D, Liu Z. Primary immunodeficiency as a cause of immune-mediated kidney diseases. Nephrol Dial Transplant 2024; 39: 1772-84.
2.
Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 update on the classification from the International Union Of Immunological Societies expert committee. J Clin Immunol 2022; 42: 1473-507.
3.
Prakash PR, Gupta G, Aggarwal M, Baitha U. Type 2 hyper-IgM syndrome with a rare variant of AICDA gene mutation in a young woman. BMJ Case Rep 2023; 16: e253878.
4.
Palterer B, Salvati L, Capone M, et al. Variants disrupting CD40L transmembrane domain and atypical X-Linked Hyper-IgM syndrome: a case report with leishmaniasis and review of the literature. Front Immunol 2022; 13: 840767.
5.
Chen X, Liu F, Yuan L, et al. Novel mutations in hyper‐IgM syndrome type 2 and X‐linked agammaglobulinemia detected in three patients with primary immunodeficiency disease. Mol Genet Genomic Med 2020; 9: e1552.
6.
Català-Moll F, Ferreté-Bonastre AG, Li T, et al. Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction. Nucleic Acids Res 2021; 49: 5057-73.
7.
Della Mina E, Jackson KJL, Crawford AJI, et al. A novel heterozygous variant in AICDA impairs Ig class switching and somatic hypermutation in human B cells and is associated with autosomal dominant HIGM2 syndrome. J Clin Immunol 2024; 44: 66.
8.
Dirks J, Haase G, Cantaert T, et al. A novel AICDA splice-site mutation in two siblings with HIGM2 permits somatic hypermutation but abrogates mutational targeting. J Clin Immunol 2022; 42: 771-82.
9.
Yazdani R, Fekrvand S, Shahkarami S, et al. The hyper IgM syndromes: Epidemiology, pathogenesis, clinical manifestations, diagnosis and management. Clin Immunol 2019; 198: 19-30.
10.
Quartier P, Bustamante J, Sanal O, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol 2004; 110: 22-9.
11.
Silva R, Da Costa JT. Hyper-IgM syndrome: a case report and a clinical perspective. Eur Ann Allergy Clin Immunol 2010; 42: 194-6.
12.
Cabral-Marques O, Klaver S, Schimke LF, et al. First report of the hyper-IgM syndrome registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes. J Clin Immunol 2014; 34: 146-56.
13.
Ouadani H, Ben-Mustapha I, Ben-ali M, et al. Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients. Immunogenetics 2016; 68: 19-28.
14.
Aghamohammadi A, Parvaneh N, Rezaei N, et al. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations. J Clin Immunol 2009; 29: 769-76.
15.
Adatia A, Ritchie B. Late-onset lymphopenia and ITP in a patient with Hyper IgM syndrome due to a homozygous variant in AICDA. J Clin Immunol 2023; 43: 1540-2..
16.
Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 2000; 102: 565-75.
17.
Wang ZQ, Meng Y, Dou Y, et al. [Clinical effect of allogeneic hematopoietic stem cell transplantation in children with hyper-IgM syndrome]. Zhongguo Dang Dai Er Ke Za Zhi 2022; 24: 635-42.
18.
Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997; 131: 47-54.
19.
Şahin O, Özdemir Ö, Erkorkmaz Ü, Aydemir Ö. Normal immunoglobulin (IgG, IgA, and IgM) values in healthy children without newborn period. Pol J Allergol 2025; 12: 172-81.
20.
Melek Arsoy H, Özdemir Ö, Dikici Ü, et al. Unexpected cause of headache in a patient with Noonan syndrome: aseptic meningitis. Pol J Allergol 2024; 11: 327-31.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
